Top Markets
Coin of the day
Perpetua Medical AB (publ) Perpetua Medical AB (publ)

Perpetua Medical AB (publ)

PERP-B
Kedudukan dalam Saham #35990
Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden... Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden specifically tailored for the application and management of injectable medications. Among its principal offerings is DrugLog, a system designed to mitigate errors in pharmacy medication dispensing. Another key product, WasteLog, serves as a device for analyzing and reconciling discarded and returned controlled injectable substances. Additionally, PrepLog, built upon the core technology of DrugLog, integrates with existing prescription or medication management systems to enable the verification of drug preparations. The company, which was established in 2007 and maintains its headquarters in Uppsala, Sweden, officially changed its name to Perpetua Medical AB (publ) in April 2024, having formerly been known as Pharmacolog i Uppsala AB (publ). Perpetua Medical AB (publ) operates as a subsidiary entity of Nolsterby Invest AB.
Harga Saham
$0.37305641
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$3.19M
Perubahan (1 hari)
-2.62%
Perubahan (1 tahun)
-22.98%
Negara
SE
Perdagangan Perpetua Medical AB (publ) (PERP-B)

Kategori

Hasil untuk Perpetua Medical AB (publ) (PERP-B)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Perpetua Medical AB (publ), hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Perpetua Medical AB (publ) dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
$6.51B -
US